IPILIMUMAB PLUS LENALIDOMIDE FOR TREATMENT OF RELAPSED DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PATIENTS (PTS) WITH LYMPHOID MALIGNANCIES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.124_2630
Abstract: vation of CD56+ NKC as opposed to NR (Figure 1). NKC cytotoxicity through the expression of Granzyme B was seen in R vs NR. Flow quantitation of circulating CD4+ CD25+ T cells (Tregs) shows a… read more here.
Keywords: plus lenalidomide; ipilimumab plus; relapsed disease; lenalidomide treatment ... See more keywords
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3648
Abstract: Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed… read more here.
Keywords: plus lenalidomide; tafasitamab plus; versus systemic; lenalidomide versus ... See more keywords
Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.8015
Abstract: 8015Background: The PD-1 inhibitor pembro blocks interaction of PD-1 with its ligands PD-L1/PD-L2, activating antitumor immunity. Combination of pembro, len, and dex may provide synergistic antitum... read more here.
Keywords: lenalidomide len; dex; pembro; plus lenalidomide ... See more keywords